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a b s t r a c t
Introduction: Metastases of solid tumors to the bone marrow are rarely reported. Clinical
manifestation and laboratory findings remain uncharacteristic and lead to misdiagnosis.
Detection of bone marrow metastases may have an impact on therapeutic decisions and is
usually associated with poor prognosis. Aim: To characterize clinical picture and hematologi-
cal findings in patients with bone marrow metastasis. Material and methods: We retrospecti-
vely reviewed medical records of patients with bone marrow metastases who were primary
misdiagnosed with hematological malignancies. Results: Ten patients at median age of 51
years at diagnosis were included. There were following findings on admission: duopenia
(n = 7), pancytopenia (n = 1), anemia (n = 1) and skeletal lytic lesions (n = 1). The diagnosis of
prior cancer was reported in 3 patients and included multiple myeloma, breast cancer and
oligoastrocytoma. Clinical manifestations were hepatomegaly (n = 4), lymphadenopathy
(n = 4), skin pallor (n = 3), cachexia (n = 2) and hemorrhagic diathesis (n = 2). Imaging studies
revealed diffuse bone lesions (n = 5), pulmonary infiltrates (n = 2) and liver masses (n = 2).
Leukoerythroblastosis was demonstrated in 4 cases. Bone marrow aspirate detected the pre-
sence of abnormal cell population in 4 patients. In all studied patients a final diagnosis was
established by immunohistochemistry of bone marrow biopsy. The following malignancies
were detected: prostate adenocarcinoma (n = 2), anaplastic microcellular carcinoma of un-
known origin (n = 2), adenocarcinoma of unknown origin (n = 2), Ewing's sarcoma (n = 1),
breast cancer (n = 1), clarocellular renal cancer (n = 1) and neuroendocrine tumor (n = 1). Nine
out of the 10 metastatic patients died shortly after chemotherapy. Conclusions: Unexplained
hematological abnormalities should arise the suspicion of bone marrow metastases.
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Data on solid tumors metastasis into the bone marrow are
scarce. Patients characteristics comes from small case series
or single case reports [1–5]. Carcinomas of breast, prostate,
lung and gastrointestinal tract in adult and Ewing's sarcoma
and neuroblastoma in children are the most frequent
neoplasms infiltrating the bone marrow [3]. Clinical mani-
festations and laboratory findings remain uncharacteristic
and may mimic common myeloid or lymphoid malignancies
and often lead to misdiagnosis. Detection of bone marrow
metastasis may have an impact on therapeutic decisions
and is usually associated with poor prognosis [6, 7]. It was
found that bone marrow has unique environment rich in
factors facilitating the growth of circulating tumor cells and
cancer progression. However, the mechanisms of this pro-
cess have not been completely defined and any risk factors
associated with cancer metastasis into the bone marrow
have been established so far [8–11].
Herein, we retrospectively investigated the clinical char-
acteristics of ten adult patients with bone marrow metasta-
sis of solid tumors.Material and methods
We retrospectively analyzed medical records of patients
with bone marrow metastasis who were suspected to have
a hematological malignancy and were referred to our
Department between years 2002–2014. Patients’ medical
records included clinical history, physical examination,
laboratory and radiological findings. Moreover, the results of
blood and bone marrow aspirates smears, histopathological
examinations of trephine biopsies as well as their immuno-
histochemical (ICH) stainings were evaluated in details. The
following set of antibodies was initially used to rule out the
hematological malignancy on bone marrow aspirate (n = 7):
CD14, CD34, CD36, CD45, CD64, CD117, IREM-2 and HLA-DR.
After the final diagnosis of solid tumor metastasis had been
established, these patients were referred to Oncology Unit
for further evaluation. Their follow-up data were obtained
after contacting the treating oncologist.Results
Ten patients at median age of 51 years (range 26–75) at the
time of first hospital admittance were included in this
analysis. Female to male ratio was 1:1.5. There have been
the following reasons of their referrals to hematology unit:
bicytopenia (n = 7), pancytopenia (n = 1), anemia (n = 1), ske-
letal lytic lesions (n = 1). Three patients had prior history of
neoplasm: (1) a 66-year old female was diagnosed with
hormone-dependent breast cancer four years before and
underwent right-side mastectomy followed by combination
of chemotherapy (4 cycles of AC regimen: doxorubicin,
cyclophosphamide), radiotherapy and hormones (detailed
data on doses and treatment duration were not available),
(2) a 44-year old female with non-secretory multiplemyeloma received chemotherapy consisting of 4 cycles
of CTD regimen (cyclophosphamide, dexamethasone thali-
domide), 4 cycles of VTD (bortezomib, thalidomide, dexa-
methasone) and 1 VAD (vincristine, doxorubicin,
dexamethasone) and finally (3) a 39-year old male patient
with glioma mixtum oligosarcoma who underwent partial
resection of his tumor and received radiotherapy (detailed
information were not available) along with chemotherapy
with PCV protocol (lomustine, procarbazine, vincristine).
The remaining 7 patients had no prior cancer history.
The most frequent symptoms presented on admission
were as follows: fatigue (n = 7) and bone/muscle pain (n = 6).
Other symptoms included: loss of appetite (n = 3), fever
(n = 2), weight loss (n = 2), dysphagia (n = 2), hemoptysis
(n = 2), dizziness (n = 1), memory loss (n = 1) and nausea
(n = 1). One patient remained asymptomatic.
Physical examination revealed hepatomegaly (n = 4), lym-
phadenopathy (n = 4), skin pallor (n = 3), cachexia (n = 2), and
hemorrhagic diathesis (n = 2). Disseminated skeletal lytic
lesions (n = 5), pulmonary infiltrates (n = 2) and liver masses
(n = 2) were found on imaging studies. All but one patient
had anemia and low platelet count was demonstrated in
7 patients. One patient was pancytopenic and no abnormal-
ities on blood test were detected in one.
Peripheral blood smear showed leukoerythroblastosis in
4 cases and left shift was noted also in 4. A normal blood
picture was demonstrated in 2 patients. None of the
patients had circulating malignant cells. Bone marrow
aspirate was successful in 7 patients. Among them 4 patients
were found with abnormal cell population, 1 was detected
with erythroid dysplasia and 3 patients had no significant
abnormalities. Dry tap was present in the remaining 3 sub-
jects. Bone marrow was hypocellular and normocellular in
6 and 4 patients, respectively. Reticulin fibrosis of grade 1–2
was found in the marrow of 4 subjects, but such data were
missing for the remaining 6 patients. In all included patients
a final diagnosis of solid tumor metastasis was established
using a wide panel of immunohistochemical markers (CK,
EMA, PAS, PAP, PSA, TTF1, RCC, vimentin, desmin and CD99)
on bone marrow biopsies The following neoplasms were
diagnosed: renal cancer (n = 1; Fig. 1), prostate cancer (n = 2;
Fig. 2), anaplastic microcellular carcinoma of unknown
origin (n = 2), adenocarcinoma of unknown origin (n = 2),
Ewing's sarcoma (n = 1), breast cancer (n = 1) and anaplastic
oligodendroglioma (n = 1). Nine out of the 10 patients died
shortly after palliative chemotherapy had started.Discussion
Cancer metastasis is the major cause of death in over 90%
of patients with solid tumors [12]. Accordingly, detection of
bone marrow metastasis is significant for clinical staging,
prognosis and has an impact on therapeutic decisions. The
metastatic process is multi-step cascade including local
invasion and migration from primary tumor, intravasation
into blood capillaries, survival in circulation, extravasation,
colonization and proliferation in distant organs [9, 10]. The
mechanisms of micrometastasis to the distal tissues
are highly regulated and involve numerous intrinsic and
[(Fig._1)TD$FIG]
Fig. 1 – Clarocellular renal cancer cells in bone marrow
[(Fig._2)TD$FIG]
Fig. 2 – Prostate adenocarcinoma cells in bone marrow
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factors promoting marrow metastasis are poorly defined.
However, this process can be explained by the unique
marrow environment that is rich in adhesion molecules,
cytokines, chemokines and growth factors [9–11, 13, 14].
Cytokines such as IL-6, IL-11, and TNF-a seem to contribute
metastasis specifically to the bone and bone marrow. It has
been stated that only 0.01% of disseminating tumor cells
(DTCs) that enter the circulation will survive and proliferate
at distant organs [8]. Factors that decrease the probability of
survival of circulating tumor cells (CTCs) include mechanical
shear stress, detachment-induced cell death and cell-
mediated cytotoxicity. Inflammatory mediators released by
cancer cells, physical interaction with leukocytes, endogen-
ous factors present in blood may enhance the ability of
CTCs to survive. The activated platelets and fibrin aggre-
gates surrounding CTCs may protect them from NK cell-
mediated lysis. Some of these factors and cytokines released
into the tumor microenvironment depend on activation ofNF-kappab and STAT3 and promote the survival of CTCs in
circulation [8, 10, 11, 13].
The time needed for activation of DTCs in marrow and
transformation into clinically presented macrometastasis is
highly variable. There are no characteristic or specific
clinical manifestations and laboratory findings which may
suggest bone marrow involvement and usually this is
present at the late stage of the neoplastic disorder. Bone
marrow metastasis is usually accompanied by anemia,
thrombocytopenia or both [1, 2, 5]. Anemia was the most
common laboratory finding in our study and it was detected
in 9 patients while thrombocytopenia was seen in 7. It is
important to highlight that unexplained hematologic
abnormalities or progressive cytopenia in cancer patients
should arouse suspicion of bone marrow involvement.
However, the peripheral blood results in patients with
marrow metastasis usually remain unremarkable [1–3, 5].
Nevertheless, the detection of leukoerythroblastosis may be
suggestive of marrow infiltration and should be further
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erythroblasts in the blood smear is highly suggestive of
bone marrow infiltration in breast cancer [1]. The current
study noted leucoerythroblastic picture only in 4 cases. In
our research, the CTCs were not found in blood smear.
However, the examination did not encompass newer techni-
ques allowing for detection of tumor cells in the peripheral
blood. According to the literature, the detection of the DTCs
in bone marrow is associated with the presence of minimal
residual disease, clinical relapse or development of metas-
tasis and may serve for follow-up after therapy [15–18]. In
this study, abnormal cell population was seen in bone
marrow aspirate in 4 patients whilst the trephine biopsy
revealed the presence of tumor cells in all 10 cases. Positive
results of trephine biopsy for tumor cells are frequently
observed while the aspirate remains often negative [19–21].
Both techniques may serve for detection of bone marrow
involvement. However, a final diagnosis is rarely based on
bone marrow aspirates only and most frequent relies on the
trephine biopsy examination confirmed by immunohisto-
chemistry panel. Classically, trephine biopsy is decisive
when there is an inability to obtain the sample of the
marrow by aspiration. It should be mentioned that identifi-
cation of marrow infiltration by cancer cells is sometimes
difficult and may be overlooked. When the bone marrow
metastasis is the first manifestation of cancer, the diagnosis
is even more challenging for physicians. In some other
cases, metastatic tumor in marrow may mimic hematologi-
cal diseases and lead to misdiagnosis. The reason for this,
among others, is that the bone marrow examination is not
a routine procedure in cancer staging. Late cancer diagnosis
reduces the chances for survival and makes treatment less
likely to succeed. The coexistence of solid tumor and bone
marrow metastasis is associated with deteriorating clinical
course and poor prognosis. Bone marrow infiltration has an
impact on overall survival 9 out of 10patients in this
research died shortly after diagnosis, regardless of che-
motherapy administered.Conclusions
To conclude, no single clinical feature is considered to be
predictive of bone marrow involvement in cancer patients.
Unexplained hematological abnormalities in clinical prac-
tice, especially anemia and thrombocytopenia, should arise
the suspicion of bone marrow metastases. Trephine biopsy
confirmed by immunohistochemistry remains a gold stan-
dard in establishing the definitive diagnosis in bone marrow
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